熱景生物(688068.SH):擬出資2億元參設投資基金
格隆匯7月6日丨熱景生物(688068.SH)公佈,公司擬使用自有資金與創景資本、杭州博日科技股份有限公司(簡稱“博日科技”)、安徽耀安投資集團有限公司(簡稱“耀安投資”)及紹興國創振德醫療產業一期股權投資合夥企業(有限合夥)(簡稱“振德醫療基金”)共同出資參與投資創景康潤。本次擬投資的基金募集規模人民幣4.75億元,公司擬以自有資金認繳出資2億元,出資比例為42.1053%。重點投資於體外診斷(IVD)、創新藥、器械、生命科學(科研與工業產業供應鏈)、技術創新、醫療健康及先進製造業等領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.